Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

- Rasmussen, Birgitte B., Regan, Meredith M., Braye, Stephen, Altermatt, Hans J., Gelber, Richard D., Castiglione-Gertsch, Monica, Goldhirsch, Aron, Gusterson, Barry A., Thürlimann, Beat, Coates, Alan S., Viale, Giuseppe, Lykkesfeldt, Anne E., Dell'Orto, Patrizia, Del Curto, Barbara, Henriksen, Katrine L., Mastropasqua, Mauro G., Price, Karen N., Méry, Eliane E., Lacroix-Triki, Magali

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

- Kneebone, Andrew, Fraser-Browne, Carol, Duchesne, Gillian M., Fisher, Richard, Frydenberg, Mark, Herschtal, Alan, Williams, Scott G., Brown, Chris, Delprado, Waeick, Haworth, Annette, Joseph, David J., Martin, Jarad M., Matthews, John H. L., Millar, Jeremy L., Sidhom, Milllar, Spry, Nigel, Tang, Colin I., Turner, Sandra, Wiltshire, Kirsty L., Woo, Henry H., Davis, Ian D., Lim, Tee S., Pearse, Maria

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

- Regan, Meredith M., Neven, Patrick, Rabaglio, Manuela, Price, Karen N., Gelber, Richard D., Coates, Alan S., Thürlimann, Beat, Giobbie-Hurder, Anita, Goldhirsch, Aron, Ejlertsen, Bent, Mauriac, Louis, Forbes, John F., Smith, Ian, Láng, István, Wardley, Andrew

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial

- Sestak, Ivana, Singh, Shalini, Eastell, Richard, Cuzick, Jack, Blake, Glen M., Patel, Rajesh, Gossiel, Fatma, Coleman, Rob, Dowsett, Mitch, Forbes, John F., Howell, Anthony

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

- Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

- The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes, John F.

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

- Cuzick, Jack, Sestak, Ivana, Pinder, Sarah E., Ellis, Ian O., Forsyth, Sharon, Bundred, Nigel J., Forbes, John F., Bishop, Hugh, Fentiman, Ian S., George, William D.

Lessons from the skin: cutaneous features of familial cancer

- Winship, Ingrid M., Dudding, Tracy E.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

- Bernhard, Jürg, Luo, Weixiu, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Ribi, Karin, Walley, Barbara A., Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio

Preventive therapy for breast cancer: a consensus statement

- Cuzick, Jack, DeCensi, Andrea, Vogel, Victor, Zwierzina, Heinz, Arun, Banu, Brown, Powell H., Castiglione, Monica, Dunn, Barbara, Forbes, John F., Glaus, Agnes, Howell, Anthony, Von Minckwitz , Gunter

Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial

- Janda, Monika, Gebski, Val, Nicklin, James L., Oehler, Martin K., Otton, Geoff, Perrin, Lewis, Salfinger, Stuart, Hammond, Ian, Leung, Yee, Walsh, Tom, Sykes, Peter, Ngan, Hextan, Brand, Alison, Garrett, Andrea, Laney, Michael, Ng, Tong Yow, Tam, Karfai, Chan, Karen, Wrede, C. David H., Pather, Selvan, Simcock, Bryony, Farrell, Rhonda, Obermair, Andreas, Hogg, Russel, Jobling, Thomas W., Land, Russel, Manolitsas, Tom, McCartney, Anthony, Nascimento, Marcelo, Neesham, Deborah

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial

- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Kenny, Lizbeth, Duchesne, Gillian, Delahunt, Brett, McElduff, Patrick, Joseph, David, Spry, Nigel A., Lamb, David S., Tai, Keen-Hun, Matthews, John, Atkinson, Chris, Turner, Sandra, Christie, David

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

- Sestak, Ivana, Cuzick, Jack, Sapunar, Francisco, Eastell, Richard, Forbes, John F., Bianco, Angelo R., Buzdar, Aman U.

Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis

- Lacas, Benjamin, Bourhis, Jean, O'Sullivan, Brian, Corvò, Renzo, Laskar, Sarbani Ghosh, Fallai, Carlo, Yamazaki, Hideya, Dobrowsky, Werner, Cho, Kwan Ho, Beadle, Beth, Langendijk, Johannes A., Viegas, Celia Maria Pais, Overgaard, Jens, Denham, James W., Zhang, Qiang, Grégoire, Vincent, Nankivell, Matthew, Zackrisson, Björn, Szutkowski, Zbigniew, Suwiński, Rafał, Poulsen, Michael

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

- Denham, James W., Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Matthews, John, Atkinson, Chris, Tai, Keen-Hun, Christie, David, Kenny, Lizbeth, Turner, Sandra, Gogna, Nirdosh Kumar, Diamond, Terry, Delahunt, Brett, Oldmeadow, Chris, Attia, John, Steigler, Allison

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Wynne, Chris, D'Este, Catherine, Lamb, David S., Joseph, David, Turner, Sandra, Matthews, John, Atkinson, Chris, North, John, Christie, David, Spry, Nigel A.

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

- D'Amico, Anthony V., Chen, Ming-Hui, de Castro, Mario, Loffredo, Marian, Lamb, David S., Steigler, Allison, Kantoff, Philip W., Denham, James W.

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

- Cuzick, Jack, Sestak, Ivana, Cawthorn, Simon, Hamed, Hisham, Holli, Kaija, Howell, Anthony, Forbes, John F.

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

- Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

- Duchesne, Gillian M., Woo, Henry H., Millar, Jeremy, Milne, Roger, Smith, Rosemary G., Spry, Nigel, Stockler, Martin, Syme, Rodney A., Tai, Keen Hun, Turner, Sandra, Bassett, Julie K., Bowe, Steven J., D'Este, Catherine, Frydenberg, Mark, King, Madeleine, Ledwich, Leo, Loblaw, Andrew, Malone, Shawn